George Wong
Neurology · Rogersville, MONPI 1508801333
Payments from drug & device makers
Across 227 payments — averaging $142.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$23K
- AbbVie$8K
- Supernus Pharmaceuticals, Inc.$302
- Sanofi$152
- EMD Serono, Inc.$115
- Acadia Pharmaceuticals Inc$113
- plus $989 from 33 others
What the payments were for
- Speaking & faculty fees$5,00059%
- Travel & lodging$1,07213%
- Food & beverage$2,39828%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 100 | $22,951 |
| AbbVie(2 entities) | 25 | $7,642 |
| Supernus Pharmaceuticals, Inc. | 17 | $302 |
| Sanofi | 9 | $152 |
| EMD Serono, Inc. | 8 | $115 |
| Acadia Pharmaceuticals Inc | 7 | $113 |
| Kyowa Kirin, Inc. | 7 | $112 |
| Amgen | 4 | $95 |
| Novartis | 4 | $79 |
| UCB, Inc. | 4 | $54 |
| Boston Scientific | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Piramal Critical Care | 2 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Biogen | 2 | $32 |
| Pfizer | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Adamas Pharmaceuticals, Inc. | 2 | $29 |
| Medtronic | 2 | $25 |
| Lundbeck LLC | 1 | $19 |
| Merz North America, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| CSL Behring | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| AstraZeneca | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Livanova USA, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| SK Life Science, Inc. | 1 | $13 |
| Banner Life Sciences, LLC | 1 | $11 |
| Strongbridge US Inc. | 1 | $11 |
| Ambu Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYOBLOC$6,264
How this compares
$32,265 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 20 | $15,273 |
| RivastigmineRivastigmine Tartrate | 26 | $1,792 |
| Lamotrigine | 26 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $14 | $15,27320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 381 neurology providers in Missouri.
Other neurology in Rogersville
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
- Siddharth KaulBridgeton$5.7M
- Kenneth SharlinOzark$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.